Table 1

Baseline demographic, clinical and biological characteristics of the study patients (n=85)

Mean±SD age, years50±13
Sex (F/M), n (%)69 (81%)/16 (19%)
Mean±SD duration of rheumatoid arthritis, months35±20
Rheumatoid factor positivity, n (%)53 (63%)
Anti-CCP antibodies positivity, n (%)54 (64%)
Erosion seen on radiography*, n (%)65 (77%)
Current medications, n (%) patientsNo treatment3 (3.5%)
Synthetic DMARDsTotal71 (83.5%)
Methotrexate61 (71.8%)
Biological agents11 (13%)
Oral steroids (<10 mg/day)38 (44.7%)
Median (IQR) patient's global assessment (VAS 0–100 scale)15 (2–21)
Median (IQR) morning stiffness, min7 (0–10)
Median (IQR) tender joint count (28 assessed)1 (0–2)
Median (IQR) swollen joint count (28 assessed)2 (2–3)
Median (IQR) ESR, mm/h13 (6–16)
Median (IQR) CRP level, mg/l5 (4–6)
Disease activity score 44Mean±SD score1.5±0.5
Patients in remission (DAS <1.6), n (%)47 (55.3%)
Patients with low disease activity (DAS 1.6–2.4), n (%)38 (44.7%)
  • RF (positive titre 40 IU).

  • * Erosion defined as Sharp score modified by van der Heijde for erosion ≥1.

  • anti-CCP, anti-cyclic citrullinated protein; CRP, C reactive protein; DAS, disease activity score; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; VAS, visual analogue scale.